Your browser doesn't support javascript.
Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production.
Chen, Yuezhou; Zuiani, Adam; Fischinger, Stephanie; Mullur, Jyotsna; Atyeo, Caroline; Travers, Meghan; Lelis, Felipe J N; Pullen, Krista M; Martin, Hannah; Tong, Pei; Gautam, Avneesh; Habibi, Shaghayegh; Bensko, Jillian; Gakpo, Deborah; Feldman, Jared; Hauser, Blake M; Caradonna, Timothy M; Cai, Yongfei; Burke, John S; Lin, Junrui; Lederer, James A; Lam, Evan Christopher; Lavine, Christy L; Seaman, Michael S; Chen, Bing; Schmidt, Aaron G; Balazs, Alejandro Benjamin; Lauffenburger, Douglas A; Alter, Galit; Wesemann, Duane R.
  • Chen Y; Department of Medicine, Division of Allergy and Immunology, Division of Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • Zuiani A; Department of Medicine, Division of Allergy and Immunology, Division of Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • Fischinger S; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
  • Mullur J; Department of Medicine, Division of Allergy and Immunology, Division of Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • Atyeo C; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
  • Travers M; Department of Medicine, Division of Allergy and Immunology, Division of Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • Lelis FJN; Department of Medicine, Division of Allergy and Immunology, Division of Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • Pullen KM; Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
  • Martin H; Department of Medicine, Division of Allergy and Immunology, Division of Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • Tong P; Department of Medicine, Division of Allergy and Immunology, Division of Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • Gautam A; Department of Medicine, Division of Allergy and Immunology, Division of Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • Habibi S; Department of Medicine, Division of Allergy and Immunology, Division of Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • Bensko J; Department of Medicine, Division of Allergy and Immunology, Division of Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • Gakpo D; Department of Medicine, Division of Allergy and Immunology, Division of Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • Feldman J; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
  • Hauser BM; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
  • Caradonna TM; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
  • Cai Y; Boston Children's Hospital, Boston, MA 02115, USA.
  • Burke JS; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
  • Lin J; Department of Medicine, Division of Allergy and Immunology, Division of Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • Lederer JA; Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA; Massachusetts Consortium on Pathogen Readiness, Boston, MA 02115, USA.
  • Lam EC; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
  • Lavine CL; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Seaman MS; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Chen B; Boston Children's Hospital, Boston, MA 02115, USA; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Schmidt AG; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA; Massachusetts Consortium on Pathogen Readiness, Boston, MA 02115, USA.
  • Balazs AB; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA; Massachusetts Consortium on Pathogen Readiness, Boston, MA 02115, USA.
  • Lauffenburger DA; Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Massachusetts Consortium on Pathogen Readiness, Boston, MA 02115, USA.
  • Alter G; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA; Massachusetts Consortium on Pathogen Readiness, Boston, MA 02115, USA.
  • Wesemann DR; Department of Medicine, Division of Allergy and Immunology, Division of Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Massachusetts Consortium on Pathogen Readiness, Boston, MA 02115, USA. Electronic address: dwesemann@bwh.harvard.edu.
Cell ; 183(6): 1496-1507.e16, 2020 12 10.
Article in English | MEDLINE | ID: covidwho-898561
ABSTRACT
Antibodies are key immune effectors that confer protection against pathogenic threats. The nature and longevity of the antibody response to SARS-CoV-2 infection are not well defined. We charted longitudinal antibody responses to SARS-CoV-2 in 92 subjects after symptomatic COVID-19. Antibody responses to SARS-CoV-2 are unimodally distributed over a broad range, with symptom severity correlating directly with virus-specific antibody magnitude. Seventy-six subjects followed longitudinally to ∼100 days demonstrated marked heterogeneity in antibody duration dynamics. Virus-specific IgG decayed substantially in most individuals, whereas a distinct subset had stable or increasing antibody levels in the same time frame despite similar initial antibody magnitudes. These individuals with increasing responses recovered rapidly from symptomatic COVID-19 disease, harbored increased somatic mutations in virus-specific memory B cell antibody genes, and had persistent higher frequencies of previously activated CD4+ T cells. These findings illuminate an efficient immune phenotype that connects symptom clearance speed to differential antibody durability dynamics.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunoglobulin G / Lymphocyte Activation / CD4-Positive T-Lymphocytes / COVID-19 / Antibodies, Viral / Antibody Formation / Mutation Type of study: Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Cell Year: 2020 Document Type: Article Affiliation country: J.cell.2020.10.051

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunoglobulin G / Lymphocyte Activation / CD4-Positive T-Lymphocytes / COVID-19 / Antibodies, Viral / Antibody Formation / Mutation Type of study: Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Cell Year: 2020 Document Type: Article Affiliation country: J.cell.2020.10.051